{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:42:46Z","timestamp":1773211366351,"version":"3.50.1"},"reference-count":39,"publisher":"Microbiology Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9,1]]},"abstract":"<jats:p>The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a surveillance study established in 2004 to monitor the activity of tigecycline, the first glycylcycline, and comparator agents [<jats:italic>\u03b2<\/jats:italic>-lactams (including penicillins, cephalosporins and carbapenems), glycopeptides, tetracyclines, fluoroquinolones and oxazolidinones] against Gram-positive and Gram-negative pathogens worldwide. This report examines 1692 isolates of <jats:italic>Staphylococcus aureus<\/jats:italic> collected in the continental United States between January 2004 and September 2005. Meticillin-resistant <jats:italic>S. aureus<\/jats:italic> (MRSA) accounted for 52.0\u200a% of isolates. Prevalence of MRSA by state ranged from 12.5\u200a% in New Hampshire to 100\u200a% in Kentucky. All isolates were susceptible to tigecycline, linezolid and vancomycin. <jats:italic>In vitro<\/jats:italic>, tigecycline was potent against both meticillin-susceptible <jats:italic>S. aureus<\/jats:italic> (MSSA) (MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub>=0.12\u2005\u03bcg\u2005ml<jats:sup>\u22121<\/jats:sup>) and MRSA (MIC<jats:sub>50<\/jats:sub>=0.12\u2005\u03bcg\u2005ml<jats:sup>\u22121<\/jats:sup>; MIC<jats:sub>90<\/jats:sub>=0.25\u2005\u03bcg\u2005ml<jats:sup>\u22121<\/jats:sup>). Only a single isolate was resistant to three or more antimicrobial classes. Ninety-six isolates (5.7\u200a%) were susceptible to the complete antimicrobial panel.<\/jats:p>","DOI":"10.1099\/jmm.0.46710-0","type":"journal-article","created":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T17:28:00Z","timestamp":1188408480000},"page":"1189-1193","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial"],"prefix":"10.1099","volume":"56","author":[{"given":"Debra A.","family":"Goff","sequence":"first","affiliation":[{"name":"The Ohio State University Medical Center, Department of Pharmacy, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[{"name":"Wyeth Pharmaceuticals, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijantimicag.2005.02.019","article-title":"Trends in linezolid susceptibility patterns: report from the 2002\u20132003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program","volume":"26","author":"Anderegg","year":"2005","journal-title":". Int J Antimicrob Agents"},{"key":"R2","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. The Tigecycline 301 and 306 Study Groups","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R3","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1473-3099(05)70243-7","article-title":"Meticillin-resistant Staphylococcus aureus : USA","volume":"5","author":"Boyce","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R7","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"R9","first-page":"376","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in Taiwan","volume":"38","author":"Chen","year":"2005","journal-title":"J Microbiol Immunol Infect"},{"key":"R10","volume-title":"Performance standard for antimicrobial susceptibility testing , document M100-S15","year":"2005"},{"key":"R11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2005.01162.x","article-title":"Methicillin-resistant Staphylococcus aureus : clinical manifestations and antimicrobial therapy","volume":"11 (Suppl. 4)","author":"Cunha","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/344326","article-title":"A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds","volume":"186","author":"Daum","year":"2002","journal-title":"J Infect Dis"},{"key":"R14","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. The Tigecycline 300 and 305 cSSSI Study Groups","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1086\/367653","article-title":"Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection","volume":"36","author":"Engemann","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijantimicag.2004.07.007","article-title":"Antimicrobial activity of tigecycline (GA-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections","volume":"24","author":"Fritsche","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"R17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.03.002","article-title":"In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections","volume":"49","author":"Fritsche","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.49.1.366-379.2005","article-title":"Analysis of the genetic variability of virulence-related loci in epidemic clones of methicillin-resistant Staphylococcus aureus","volume":"49","author":"Gomes","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/jac\/dkf009","article-title":"Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials","volume":"49","author":"Graffunder","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/pmj.78.921.385","article-title":"Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit","volume":"78","author":"Haddadin","year":"2002","journal-title":"Postgrad Med J"},{"key":"R22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.44.6.1549-1555.2000","article-title":"A new class of genetic element, staphylococcus cassette chromosome mec , encodes methicillin resistance in Staphylococcus aureus","volume":"44","author":"Katayama","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R24","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1086\/430791","article-title":"Evolving concepts of pharmaceutical company-sponsored surveillance studies","volume":"41 (Suppl. 4)","author":"Koeth","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R25","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.49.5.1865-1871.2005","article-title":"A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline","volume":"49","author":"McAleese","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3201\/eid1106.040641","article-title":"Methicillin-resistant Staphylococcus aureus in community-acquired skin infections","volume":"11","author":"Moran","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004","volume":"32","year":"2004","journal-title":"Am J Infect Control"},{"key":"R28","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , document M7-A6","year":"2003"},{"key":"R29","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/AAC.00629-06","article-title":"Redefining a structural variant of staphylococcal cassette chromosome mec , SCC mec type VI","volume":"50","author":"Oliveira","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3949\/ccjm.72.3.235","article-title":"The emergence of methicillin-resistant Staphylococcus aureus in the community","volume":"72","author":"Padmanabhan","year":"2005","journal-title":"Cleve Clin J Med"},{"key":"R31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00000441-200508000-00007","article-title":"Clinical characteristics of linezolid-resistant Staphylococcus aureus infections","volume":"330","author":"Peeters","year":"2005","journal-title":"Am J Med Sci"},{"key":"R32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1086\/345436","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus : a meta-analysis of prevalence and risk factors","volume":"36","author":"Salgado","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R33","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1128\/JCM.42.12.5673-5680.2004","article-title":"Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin","volume":"42","author":"Stemper","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3201\/eid1106.050156","article-title":"Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States","volume":"11","author":"Stevenson","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R35","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1086\/430788","article-title":"Community-associated methicillin-resistant Staphylococcus aureus","volume":"41","author":"Weber","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R37","volume-title":"Tygacil product insert","year":"2005"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1086\/382361","article-title":"Clinical, epidemiologic, and molecular evaluation of a clonal outbreak of methicillin-resistant Staphylococcus aureus infection","volume":"38","author":"Young","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R39","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1086\/431670","article-title":"Overview of antibiotic use and resistance: setting the stage for tigecycline","volume":"41","author":"Zinner","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.46710-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T06:24:40Z","timestamp":1600842280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.46710-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.46710-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,1]]}}}